Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
Find more results for GALE
1.58
Aug 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.10 - 2.50
Open     -
Vol / Avg. 0.00/1.62M
Mkt cap 242.57M
P/E     -
Div/yield     -
EPS -0.29
Shares 161.72M
Beta 1.26
Inst. own 18%
Nov 2, 2015
Q3 2015 Galena Biopharma Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 10, 2015
Galena Biopharma Inc at BioCentury NewsMakers in the Biotech Industry Conference - 11:30AM EDT - Add to calendar
Sep 8, 2015
Galena Biopharma Inc at Rodman & Renshaw Global Investment Conference Add to calendar
Aug 6, 2015
Q2 2015 Galena Biopharma Inc Earnings Call - Webcast
Aug 6, 2015
Q2 2015 Galena Biopharma Inc Earnings Release
Jun 19, 2015
Galena Biopharma Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -463.04% -392.81%
Operating margin -330.75% -558.56%
EBITD margin - -550.84%
Return on average assets -59.66% -43.46%
Return on average equity -115.84% -170.48%
Employees 57 -
CDP Score - -

Address

4640 SW Macadam Ave Ste 270
PORTLAND, OR 97239-4232
United States - Map
+1-855-8554253 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drugs include Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain and Zuplenz (ondansetron) Oral Soluble Film is approved by the Food and Drug Administration in adult patients for the prevention of emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting.

Officers and directors

Sanford J. Hillsberg J.D. Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark W. Schwartz Ph.D. President, Chief Executive Officer, Independent Director
Age: 58
Bio & Compensation  - Reuters
Ryan M. Dunlap CPA Chief Financial Officer, Vice President, Secretary
Age: 45
Bio & Compensation  - Reuters
Joseph Lasaga Vice President - Business Development
Bio & Compensation  - Reuters
Thomas J. Knapp Interim General Counsel
Age: 62
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 64
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Irving M. Einhorn Independent Director
Age: 72
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven A. Kriegsman Independent Director
Age: 73
Bio & Compensation  - Reuters